About Aclarion, Inc.
https://www.aclarion.comAclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software.
CEO
Brent Ness
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
EMPERY ASSET MANAGEMENT, LP
Shares:110K
Value:$3.72K
CAPTRUST FINANCIAL ADVISORS
Shares:78.4K
Value:$2.65K
PALISADES HUDSON ASSET MANAGEMENT, L.P.
Shares:56K
Value:$1.89K
Summary
Showing Top 3 of 9
About Aclarion, Inc.
https://www.aclarion.comAclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $18.94K ▼ | $1.84M ▲ | $-1.71M ▼ | -9.01K% ▼ | $-2.93 ▼ | $-1.65M ▼ |
| Q2-2025 | $19.32K ▲ | $1.74M ▲ | $-1.6M ▲ | -8.29K% ▲ | $-2.75 ▲ | $-1.55M ▲ |
| Q1-2025 | $18.99K ▲ | $1.49M ▼ | $-2.04M ▼ | -10.73K% ▲ | $-9.32 ▲ | $-1.98M ▼ |
| Q4-2024 | $10.23K ▼ | $1.8M ▲ | $-1.99M ▼ | -19.44K% ▼ | $-1.59K ▼ | $-1.94M ▼ |
| Q3-2024 | $14.41K | $1.29M | $-1.37M | -9.48K% | $-1.32K | $-1.24M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $11.34M ▼ | $13.2M ▼ | $699.75K ▲ | $12.5M ▼ |
| Q2-2025 | $12.86M ▼ | $14.75M ▼ | $564.42K ▼ | $14.19M ▼ |
| Q1-2025 | $14.75M ▲ | $16.48M ▲ | $699.03K ▼ | $15.78M ▲ |
| Q4-2024 | $453.66K ▼ | $2.12M ▼ | $1.15M ▲ | $970.06K ▼ |
| Q3-2024 | $1.31M | $3.19M | $678.27K | $2.51M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.71M ▼ | $-1.16M ▲ | $-40.15K ▲ | $-283.8K ▼ | $-1.48M ▲ | $-1.17M ▲ |
| Q2-2025 | $-1.6M ▲ | $-1.87M ▲ | $-44K ▲ | $-1 ▼ | $-1.91M ▼ | $-1.87M ▲ |
| Q1-2025 | $-2.04M ▼ | $-2.51M ▼ | $-78.29K ▼ | $16.89M ▲ | $14.3M ▲ | $-2.59M ▼ |
| Q4-2024 | $-1.99M ▼ | $-899.49K ▲ | $-60.72K ▲ | $101.77K ▼ | $-858.44K ▼ | $-904.6K ▲ |
| Q3-2024 | $-1.37M | $-1.06M | $-103.7K | $1.3M | $139.41K | $-1.16M |
CEO
Brent Ness
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
EMPERY ASSET MANAGEMENT, LP
Shares:110K
Value:$3.72K
CAPTRUST FINANCIAL ADVISORS
Shares:78.4K
Value:$2.65K
PALISADES HUDSON ASSET MANAGEMENT, L.P.
Shares:56K
Value:$1.89K
Summary
Showing Top 3 of 9